tradingkey.logo

Evolus Inc

EOLS
查看详细走势图
6.900USD
+0.050+0.73%
收盘 12/26, 16:00美东报价延迟15分钟
446.89M总市值
亏损市盈率 TTM

Evolus Inc

6.900
+0.050+0.73%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.73%

5天

-2.40%

1月

-1.99%

6月

-24.51%

今年开始到现在

-37.50%

1年

-37.78%

查看详细走势图

TradingKey Evolus Inc股票评分

单位: USD 更新时间: 2025-12-26

操作建议

Evolus Inc当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在药品行业排名52/158位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价18.50。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Evolus Inc评分

相关信息

行业排名
52 / 158
全市场排名
130 / 4563
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 7 位分析师
买入
评级
18.500
目标均价
+165.42%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Evolus Inc亮点

亮点风险
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
业绩高增长
公司营业收入稳步增长,连续3年增长79.17%
估值高估
公司最新PE估值-7.59,处于3年历史高位
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值20.74K
活跃度增加
近期活跃度增加,过去20天平均换手率1.68

Evolus Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Evolus Inc简介

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
公司代码EOLS
公司Evolus Inc
CEOMoatazedi (David)
网址https://www.evolus.com/

常见问题

Evolus Inc(EOLS)的当前股价是多少?

Evolus Inc(EOLS)的当前股价是 6.900。

Evolus Inc的股票代码是什么?

Evolus Inc的股票代码是EOLS。

Evolus Inc股票的52周最高点是多少?

Evolus Inc股票的52周最高点是17.120。

Evolus Inc股票的52周最低点是多少?

Evolus Inc股票的52周最低点是5.710。

Evolus Inc的市值是多少?

Evolus Inc的市值是446.89M。

Evolus Inc的净利润是多少?

Evolus Inc的净利润为-50.42M。

现在Evolus Inc(EOLS)的股票是买入、持有还是卖出?

根据分析师评级,Evolus Inc(EOLS)的总体评级为买入,目标价格为18.500。

Evolus Inc(EOLS)股票的每股收益(EPS TTM)是多少

Evolus Inc(EOLS)股票的每股收益(EPS TTM)是-0.909。
KeyAI